Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03104439
- Locations
- 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT03101566
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Threshold Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT03098160
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 113
- Registration Number
- NCT03097939
- Locations
- 🇸🇬
National Cancer Center Singapore, Singapore, Singapore
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 31
- Registration Number
- NCT03091491
- Locations
- 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2024-11-01
- Target Recruit Count
- 50
- Registration Number
- NCT03071406
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 378
- Registration Number
- NCT03070392
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03048136
- Locations
- 🇵🇪
Local Institution, Lima, Peru
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 21
- Registration Number
- NCT03043599
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1322
- Registration Number
- NCT03036098
- Locations
- 🇺🇸
Local Institution - 0001, Anchorage, Alaska, United States
🇺🇸Local Institution - 0115, Fresno, California, United States
🇺🇸St Joseph Heritage Healthcare, Santa Rosa, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.